Impact of Cangrelor on Outcomes After Percutaneous Coronary Intervention for Acute Coronary Syndrome in High Bleeding Risk Patients

Antiplatelet medications, including P2Y12-receptor inhibitors, are used to reduce the risk of thrombotic complications of percutaneous coronary intervention (PCI).1,2 Cangrelor is a potent, short-acting, intravenous P2Y12 inhibitor that provides a rapid onset and offset of action. Early clinical trials and recent observational studies suggest that cangrelor reduces acute coronary thrombus burden and may serve as an effective bailout strategy for thrombotic complications during PCI, though this benefit comes with a modest increase in bleeding risk.